Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2014-04-24 | Steve R. Carchedi was appointed to the Board on June 7, 2013. He serves on the Audit and Compensation Committees. Non-employee directors receive quarterly payments and stock options. The compensation table shows total compensation of $134,069 for 2013. |
| 2015-04-28 | Steve R. Carchedi has served as the Chief Executive Officer of Cornerstone Pharmaceuticals, Inc., a clinical stage, oncology-focused pharmaceutical company, since October 2014. Mr. Carchedi previously served as the President, Commercial Operations for Mallinckrodt Specialty Pharmaceuticals, the Pharmaceuticals business of Covidien plc from 2012 to 2013. Having held key positions at several leading multinational pharmaceutical companies, previously, he served as Chief Marketing Officer for General Electric (GE) Healthcare-MDx where he was responsible for leading worldwide marketing for GE's Medical Diagnostics business. Prior to joining GE Healthcare, Mr. Carchedi held senior commercial leadership positions at Endo Pharmaceuticals, Enzon Pharmaceuticals and McNeil Specialty Pharmaceuticals, a subsidiary of Johnson & Johnson, Eli Lilly & Company and Bristol Myers Squibb. Mr. Carchedi holds a Bachelor of Science in marketing from the West Chester University and a Masters in Business Administration in marketing from Drexel University. Mr. Carchedi also currently serves on the board of directors of Bionumerik Pharmaceuticals, Inc. The Board has concluded that Mr. Carchedi should serve on our Board due to his experience in oncology drug development and commercialization, which the Board believes are valuable as we continue our drug development efforts. Director Compensation Table: Steve R. Carchedi Fees Earned or Paid in Cash ($): $47,500, Option Awards ($): $87,038, Total ($): $134,538. |
| 2016-04-25 | Steve R. Carchedi serves on the Audit Committee and Compensation Committee. The Director Compensation Table shows total compensation of $132,152. |
| 2017-04-20 | Steve R. Carchedi currently serves as the Chief Executive Officer and President of Apexian Pharmaceuticals, Inc. ... The Board has concluded that Mr. Carchedi should serve on our Board due to his experience in oncology drug development and commercialization. ... The following table sets forth the compensation information for our non-employee directors for the year ended December 31, 2016. Steve R. Carchedi received total compensation of $69,240. |
| 2018-04-25 | Steve R. Carchedi currently serves as the Chief Executive Officer and President of Apexian Pharmaceuticals, Inc. ... The Board has concluded that Mr. Carchedi should serve on our Board due to his experience in oncology drug development and commercialization. ... On May 31, 2017, Mr. Carchedi was appointed as the Chairperson of the Audit Committee. ... Steve R. Carchedi 61,250 fees earned, 58,915 option awards, total 120,165. |
| 2019-04-12 | Steve R. Carchedi currently serves as the Chief Executive Officer and President of Apexian Pharmaceuticals, Inc. ... Committees: Audit Committee, Compensation Committee (Chairman). ... Director Compensation Table: Steve R. Carchedi Fees Earned or Paid in Cash $67,500, Option Awards $42,740, Total $110,240. |
| 2020-04-28 | Steve R. Carchedi currently serves as the Chief Executive Officer and President of Apexian Pharmaceuticals, Inc. The Director Compensation Table shows total compensation of $111,108 for 2019. He serves on the Audit Committee and is Chairman of the Compensation Committee. |
Data sourced from SEC filings. Last updated: 2026-03-09